QUINAGLUTE
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUINAGLUTE is an oral extended-release tablet approved in 1969 as a small-molecule NDA. The generic name and mechanism of action are not specified in available data. This is a legacy product currently approaching loss of exclusivity.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); commercial teams likely focused on transition planning and defensive strategies rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No current job openings are linked to QUINAGLUTE, indicating minimal active hiring. Working on a LOE-approaching product typically involves defensive commercial strategies, supply chain management, and transition planning rather than market expansion. This is a mature/legacy brand role suited for experienced professionals managing decline or transition scenarios.
Brand Manager
Worked on QUINAGLUTE at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.